From the Editor

Friday, December 23, 2016 Published in Impact July 2012 Written by Cepheid

Welcome to the third issue of IMPACT, a quarterly magazine published by Cepheid’s Systems & Solutions Group.

Less Uncertainty — Better Safety — More Healthy Newborns

Friday, December 23, 2016 Published in Impact July 2012 Written by Dr. Najoua El Helali, Microbiologiste, Hôpital Paris-Saint-Joseph

Paris-Saint-Joseph Hospital reduces GBS infection rate and improves patient management with Xpert® GBS and GeneXpert® System.

Q&A with Dr. Najoua El Helali

Friday, December 23, 2016 Published in Impact July 2012 Written by Dr. Najoua El Helali, Microbiologiste, Hôpital Paris-Saint-Joseph

Dr. Najoua El Helali discusses the diagnosis of intrapartum screening using the Cepheid Xpert GBS molecular test.

The C. difficile Challenge

Friday, December 23, 2016 Published in Impact July 2012 Written by Laureen Haynes, MT(ASCP), Systems and Solutions Manager, Cepheid

A Typical Patient Pathway

This year the “superbug” that continues to challenge our health care systems across the country and around the world is C. difficile. The Healthcare Cost and Utilization Project (HCUP) has documented how the average cost to treat a C. difficile healthcare-associated infection (HAI) has jumped from approximately $3,600 (2001)1 to $22,500 (2009)2 per event, and length of stay (LOS) from 3 days to 11.5 days. This increase can be specifically correlated with the appearance and spread of a hyper-virulent strain (NAP1/027). At the same time, the rate of CDI stays has also increased, as shown in Figure 2. Translated across the patient population, the number of CDI-related stays has increased four-fold2.

Xperience Cepheid — Everywhere

Friday, December 23, 2016 Published in Impact July 2012 Written by Jared Tipton, Senior Director of Corporate Communications, Cepheid

Cepheid is talking mobile. Not the LOL, IMHO, and OMG kind of mobile talk. We’re talking road trip here — and our incredible new Mobile Xperience Center. We’ve taken our entire family of industry-leading GeneXpert® Systems, from the portable GX-I to the high-throughput Infinity-80, and put them into a one-of-a-kind experience on wheels.

Beginning this year, we’re bringing our unique story directly to you. Throughout the country, Xperience Center guests will now have the opportunity to interact with Cepheid’s most innovative products — right at their institution doorstep.

Just the Facts

Friday, December 23, 2016 Published in Impact July 2012 Written by Cepheid

FACT.
Preventing further complications in patients who develop infections after surgery to replace a knee or hip could save the U.S. healthcare system as much as $65 million annually, according to an analysis presented at the APIC Annual meeting in June.*